Literature DB >> 66973

Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function.

S T Crooke, F Luft, A Broughton, J Strong, K Casson, L Einhorn.   

Abstract

Serum and plasma bleomycin concentrations were determined in a patient with renal dysfunction at two creatinine clearances. The results obtained with a new radioimmunoassay and the microbiologic assay were compared. It was shown: 1) that the clearance of bleomycin from the blood is markedly retarded in severe renal dysfunction, 2) that clearance of bleomycin varies with creatinine clearance, 3) that bleomycin is probably not dialyzable, 4) that determinations on serum and plasma were equivalent, and 5) that the radioimmunoassay and microbiologic assays gave equivalent results (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66973     DOI: 10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

2.  Bleomycin pharmacokinetics in man. I. Intravenous administration.

Authors:  D S Alberts; H S Chen; R Liu; K J Himmelstein; M Mayersohn; D Perrier; J Gross; T Moon; A Broughton; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer--dosimetric and biokinetic aspects.

Authors:  K J Kairemo; H A Ramsay; M Tagesson; A P Jekunen; T K Paavonen; H A Jääskelä-Saari; K Liewendahl; K Ljunggren; S Savolainen; S E Strand
Journal:  Eur J Nucl Med       Date:  1996-06

4.  Bleomycin clinical pharmacology by radioimmunoassay.

Authors:  S W Hall; J E Strong; A Broughton; M L Frazier; R S Benjamin
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report.

Authors:  Haruki Hirakawa; Chiho Nakashima; Tomomi Nakamura; Masanori Masuda; Taro Funakoshi; Shunsaku Nakagawa; Takahiro Horimatsu; Kazuo Matsubara; Manabu Muto; Shinya Kimura; Naoko Sueoka-Aragane
Journal:  J Med Case Rep       Date:  2017-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.